LAVAL, QC, Oct. 17 /CNW/ - BioSyntech, Inc. (TSX: BSY) (the Company)
announced today that Mr. Claude LeDuc has tendered his resignation, effective
December 31, 2008, as CEO of the Company to pursue other interests. He also
resigned immediately as a member of the Board. Mr. Michel Lagueux, currently
Executive Chairman of the Board of Directors, will step in to oversee day to
day operations and ensure attainment of near term objectives.
Mr. Lagueux said: "I would like to take this opportunity on behalf of the
Board of Directors to thank Mr. LeDuc for his continued dedication and overall
effort in establishing BioSyntech as a leader in the field of cartilage
repair. Claude's contribution has established a foundation for which the
Company should benefit in years to come."
The Company also announced today the appointment of Mr. Jean Pierre
Desmarais as member of the Board of Directors. Mr. Desmarais has been working
in the medical device industry for over 30 years. Currently and for the last
12 years, Mr. Desmarais has been employed by CryoCath Technologies Inc. as
Chief Scientific Officer responsible for Regulatory Affairs and Clinical
Research. Previously he has worked for Smith and Nephew in the orthopedic and
wound healing field and at Davis and Geck surgical - as a result Mr. Desmarais
brings in depth regulatory affairs knowledge and has successfully navigated
the FDA (US regulatory authority) from IDE to PMA approval on numerous
occasions in addition to Canadian and European regulatory authorities. Mr.
Desmarais also brings a wealth of knowledge and experience in the
implementation of quality systems achieving ISO certification.
Mr. M Lagueux, Chairman of the Board of Directors, said "It's not often
that a company has the opportunity or the capacity to attract such an
accomplished and talented individual. The Board of Directors and the Company
look forward to working closely with Mr. Desmarais."
BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. Biosyntech's
platform technology is a family of hydrogels called BST-Gel(R), some of which
are liquid at low temperature and solid at human body temperature. These gels
can be injected or applied to a specific local site and offer beneficial
properties for the local repair of damaged tissue such as cartilage, bone and
chronic wounds and provide the benefit of avoiding invasive surgery. The
Company's lead, late-stage product, BST-CarGel(R) is currently undergoing an
international pivotal trial. For additional information, visit
For further information:
For further information: BioSyntech, Inc., Mr. Michel Lagueux, Executive
Chairman, Tel: (450) 686-2437, Michel.Lagueux@biosyntech.com